Artwork

Content provided by Mansueto Ventures and Fast Company. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Mansueto Ventures and Fast Company or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Ozempic and Wegovy: How 2 diabetes medications became the most popular weight-loss drugs

57:14
 
Share
 

Manage episode 390664087 series 2973437
Content provided by Mansueto Ventures and Fast Company. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Mansueto Ventures and Fast Company or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

In the United States, nearly three-quarters of adults qualify as overweight or obese, 42% of whom are considered obese. The World Obesity Federation predicts that 51% of the global population will be overweight or obese by 2035.

‘Fast Company’ contributing writer Adam Bluestein joined us to break down how Novo Nordisk, the company behind Ozempic and Wegovy, developed and marketed its weight-loss drugs. He also explained why the drugs have become so popular in the U.S., how drug pricing is extremely complicated and . . . how the medications actually work to help people lose weight.

Also, we chatted with Trina Spear about how she founded Figs, a DTC healthcare apparel company.

  continue reading

95 episodes

Artwork
iconShare
 
Manage episode 390664087 series 2973437
Content provided by Mansueto Ventures and Fast Company. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Mansueto Ventures and Fast Company or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

In the United States, nearly three-quarters of adults qualify as overweight or obese, 42% of whom are considered obese. The World Obesity Federation predicts that 51% of the global population will be overweight or obese by 2035.

‘Fast Company’ contributing writer Adam Bluestein joined us to break down how Novo Nordisk, the company behind Ozempic and Wegovy, developed and marketed its weight-loss drugs. He also explained why the drugs have become so popular in the U.S., how drug pricing is extremely complicated and . . . how the medications actually work to help people lose weight.

Also, we chatted with Trina Spear about how she founded Figs, a DTC healthcare apparel company.

  continue reading

95 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide